Perigon Wealth Management LLC Grows Position in BioNTech SE (NASDAQ:BNTX)

Perigon Wealth Management LLC boosted its stake in shares of BioNTech SE (NASDAQ:BNTX) by 3.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,902 shares of the company’s stock after purchasing an additional 224 shares during the period. Perigon Wealth Management LLC’s holdings in BioNTech were worth $666,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Fred Alger Management LLC acquired a new stake in shares of BioNTech during the 3rd quarter worth $59,485,000. Baillie Gifford & Co. grew its position in BioNTech by 0.4% during the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after acquiring an additional 31,773 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in BioNTech by 63.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock worth $2,249,000 after acquiring an additional 7,340 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of BioNTech by 123.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock worth $15,919,000 after purchasing an additional 74,119 shares during the period. Finally, SG Americas Securities LLC lifted its stake in shares of BioNTech by 412.3% in the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock valued at $4,726,000 after purchasing an additional 33,375 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on BNTX shares. BMO Capital Markets reissued an “outperform” rating on shares of BioNTech in a research report on Monday, December 2nd. Berenberg Bank assumed coverage on shares of BioNTech in a research note on Tuesday, November 19th. They issued a “buy” rating and a $130.00 target price on the stock. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and upped their price target for the stock from $110.00 to $125.00 in a research report on Tuesday, November 19th. Truist Financial started coverage on BioNTech in a research report on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective on the stock. Finally, Canaccord Genuity Group boosted their price objective on BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research note on Wednesday, November 27th. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $142.72.

BioNTech Stock Up 2.4 %

Shares of NASDAQ:BNTX opened at $123.77 on Friday. The firm has a market cap of $29.67 billion, a PE ratio of -58.94 and a beta of 0.18. The company has a fifty day simple moving average of $117.34 and a 200 day simple moving average of $107.05. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.73 EPS. On average, equities research analysts anticipate that BioNTech SE will post -3.77 EPS for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.